| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5687678 | The Journal of Urology | 2016 | 35 Pages |
Abstract
SETD2 is a potential prognostic biomarker for overall survival and progression-free survival prediction in patients with metastatic renal cell carcinoma receiving targeted therapy. However, it remains to be seen whether this is generalizable to other ethnicities and prospective external validation is required.
Keywords
SETD2immunoreactivity scoreIRSVHLmRCCccRCCTKIRCCPFsvon Hippel-LindauImmunohistochemistryIHCSurvivalprogression-free survivaldisease-free survivaloverall survivalClear cell renal cell carcinomaRenal cellNeoplasm metastasisTyrosine kinase inhibitorBiomarkersRenal cell carcinomaMetastatic renal cell carcinomaCarcinoma
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Jiajun Wang, Li Liu, Yang Qu, Wei Xi, Yu Xia, Qi Bai, Ying Xiong, Qilai Long, Jiejie Xu, Jianming Guo,